RxDoctor Payments Data

Rana Tariq, MD

Cardiovascular Disease · Braselton, GANPI 1023423845

Payments from drug & device makers

$2,252in general payments, 2019–2025

Across 48 payments — averaging $46.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$400
  • Boston Scientific$366
  • Abiomed$254
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$201
  • Astellas Pharma US Inc$173
  • E.r. Squibb & Sons, L.L.C.$162
  • plus $696 from 12 others

What the payments were for

  • Food & beverage$2,07992%
  • Education$1738%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,252 in reported general payments places this provider in the 45th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$151,290
Medicare patients
2,223
Services billed
3,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban347$337,724
JardianceEmpagliflozin200$212,338
EntrestoSacubitril/Valsartan148$189,552
XareltoRivaroxaban45$49,223
Repatha SureclickEvolocumab46$44,595
FarxigaDapagliflozin Propanediol39$37,416
OzempicSemaglutide28$26,468
MounjaroTirzepatide15$25,030
BrilintaTicagrelor20$20,423
VascepaIcosapent Ethyl59$19,337
Metoprolol Succinate518$7,017
Carvedilol731$5,616
Rosuvastatin Calcium327$5,387
Ezetimibe89$4,919
Atorvastatin Calcium405$4,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$400$337,724347 claims
NovartisEntresto$116$189,552148 claims
AstraZenecaFarxiga, Brilinta$39$57,83959 claims
Johnson & JohnsonXarelto$33$49,22345 claims
Novo NordiskOzempic$41$26,46828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Braselton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →